Update on Stem Cell‐Based Therapy and Mechanical Cardiac Support: A North American Perspective

Can tissue engineering produce bioartificial organs for transplantation?

“…This issue has been already discussed in this journal and, in the long term, represents a promising direction in overcoming current challenges . In the intermediate term, immediately available advantages of artificial organs can be combined with tissue engineering as it has been shown with combining mechanical cardiac support with the regenerative potential of stem cells …”

“…36 In the intermediate term, immediately available advantages of artificial organs can be combined with tissue engineering as it has been shown with combining mechanical cardiac support with the regenerative potential of stem cells. 37…”

Clinical implications of LDH isoenzymes in hemolysis and continuous‐flow left ventricular assist device‐induced thrombosis

“…Blood pumps or continuous‐flow left ventricular assist devices (CF‐LVADs), either in the form of implantable or extracorporeal devices, have emerged as a promising therapeutic alternative for end‐stage heart failure . With growing utilization of CF‐LVADs for end‐stage heart failure, adverse events remain common leading to significant patient morbidity and mortality . One such major complication is pump thrombosis.…”

“…3,[8][9][10] With growing utilization of CF-LVADs for end-stage heart failure, adverse events remain common leading to significant patient morbidity and mortality. [11][12][13][14][15][16][17][18][19][20] One such major complication is pump thrombosis. The incidence of pump thrombosis has been estimated to be between 1.4% and 13.9%, and is largely dependent on the device.…”

Vakhtang Tchantchaleishvili, MD to Serve as a Co‐Editor of Adult Circulatory Support for Artificial Organs

“…From this particular standpoint, his research interests include cerebrospinal fluid circulation in LVAD patients with diminished or absent pulse, algorithms for full adjustability of continuous flow, energy sources allowing full device implantability (among others, Plutonium 238), and development of biohybrid and bioartificial organs . He has worked as a research fellow at Bern University Hospital in Bern, Switzerland, Medical University of Innsbruck in Innsbruck, Austria, and Brigham and Women's Hospital in Boston, MA, USA studying various stem cells types for myocardial recovery . His further interests include education of future surgeons, 3D modeling and virtual fitting of implantable devices, using machine learning in developing better‐tailored clinical prediction models, and the history of artificial organs …”